

## Special Issue

# Unravel Metabolism and Resistance Mechanisms in Glioblastoma

### Message from the Guest Editors

Glioblastomas are highly aggressive brain tumors, among the most deadly and incurable types of human cancer, which are greatly resistant to the standard treatments that are currently available. Cancer cells can metabolically adapt to changes in oxygen or nutrients in the microenvironment, making the dysregulation of cellular metabolism a hallmark of cancer, and a critical event in therapy resistance. Once identified, cellular metabolic susceptibilities could be exploited as novel therapeutic strategies. In this Special Issue of *Metabolites*, we invite authors to submit contributions that provide novel findings in the field of glioblastoma. We plan to cover the latest advances in research on the basic mechanisms by which cellular metabolic reprogramming modulates cancer development and its role in the mechanisms of drug resistance, as well as the potential of repurposing drugs for glioblastoma-combined therapies. We welcome findings from basic research in both preclinical or clinical fields. Reviews that comprehensively highlight new findings in these field are also welcome.

### Guest Editors

Dr. Ana Luísa De Sousa-Coelho


1. Escola Superior de Saúde, Universidade do Algarve (ESSUAIG), Campus de Gambelas, 8005-139 Faro, Portugal 2. Algarve Biomedical Centre Research Institute (ABC-RI), Campus de Gambelas, 8005-139 Faro, Portugal

Dr. Bibiana I. Ferreira

1. Faculdade de Medicina e Ciências Biomédicas (FMCB), Campus de Gambelas, Universidade do Algarve, 8005-139 Faro, Portugal 2. Algarve Biomedical Center Research Institute, ABC-RI, 8005-139 Faro, Portugal

### Deadline for manuscript submissions

closed (30 June 2023)



## Metabolites

an Open Access Journal  
by MDPI

Impact Factor 3.7  
CiteScore 6.9  
Indexed in PubMed



[mdpi.com/si/122092](https://mdpi.com/si/122092)

*Metabolites*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[metabolites@mdpi.com](mailto:metabolites@mdpi.com)

[mdpi.com/journal/  
metabolites](https://mdpi.com/journal/metabolites)





# Metabolites

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.7  
CiteScore 6.9  
Indexed in PubMed



[mdpi.com/journal/  
metabolites](https://mdpi.com/journal/metabolites)



## About the Journal

### Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

---

### Editor-in-Chief

Dr. Amedeo Lonardo  
Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-  
Universitaria, 41126 Modena, Italy

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q2 (Endocrinology, Diabetes and Metabolism)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.4 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the first half of 2025).